Q-Line Biotech SME IPO GMP History
Q-Line Biotech SME IPO has been listed on May 29, 2026 at a listing price of ₹452, against the issue price of ₹343 — a gain of ₹109 (+31.78%). The GMP peaked at ₹140 on 21 May 2026 and reached a low of ₹42 on 18 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Q-Line Biotech SME IPO raised ₹251 Cr. through its IPO at a price band of ₹326 to ₹343 per share, with a lot size of 400 shares. The IPO was open for subscription from 21 May 2026 to 25 May 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 27 May 2026 | ₹ 108 | ▲ | 31% | — | — |
| 26 May 2026 | ₹ 99 | ▼ | 29% | — | — |
| 25 May 2026 | ₹ 126 | ▼ | 37% | — | — |
| 23 May 2026 | ₹ 130 | ▲ | 38% | — | — |
| 22 May 2026 | ₹ 120 | ▼ | 35% | — | — |
| 21 May 2026 | ₹ 140 | ▲ | 41% | — | — |
| 20 May 2026 | ₹ 110 | ▲ | 32% | ₹ 800 | — |
| 19 May 2026 | ₹ 69 | ▲ | 20% | ₹ 800 | — |
| 18 May 2026 | ₹ 42 | — | 12% | — | — |
Q-Line Biotech SME IPO dates
Key dates from opening to listing. Today is 3 October.
- Open 21 May 2026
- Close 25 May 2026
- Allotment 26 May 2026
- Refund/credit 27 May 2026
- Listing 29 May 2026
Q-Line Biotech SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹343 |
|---|---|
| GMP-based estimate (pre-listing) | ₹451 (+31.5%) |
| Listing gain / loss | +₹109 per share |
| Listing date | 29 May, 2026 |
| Actual listing price | ₹452 (+31.78%) |
Is Q-Line Biotech SME IPO GMP reliable?
Grey market premium for Q-Line Biotech SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Q-Line Biotech SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Q-Line Biotech SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Q-Line Biotech SME IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Q-Line Biotech SME IPO
Q-Line Biotech was incorporated in 2010 and is engaged in the business of developing, manufacturing, and supplying in-vitro diagnostic (IVD) products and medical diagnostic equipment. The company started with a focus on healthcare diagnostics and has gradually expanded its portfolio across clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, ELISA kits, rapid testing kits, and pathology equipment. It operates manufacturing facilities in Delhi and serves hospitals, diagnostic laboratories, and medical colleges across India through a wide distributor network.
The company is promoted by Saurabh Garg along with Amita Garg and other promoter group members. Q-Line Biotech follows a business model focused on indigenous manufacturing, imports, distribution, and after-sales support for diagnostic instruments and consumables. The company emphasises affordable healthcare solutions under the “Make in India” initiative while investing in research, quality control, and technology-driven manufacturing to strengthen its position in the Indian diagnostic industry.
Frequently asked
What is the GMP of Q-Line Biotech SME IPO?
The current Grey Market Premium (GMP) of Q-Line Biotech SME IPO is ₹ 108.
What is the Kostak Price of Q-Line Biotech SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Q-Line Biotech SME IPO is not available.
What is the Subject to Sauda Price of Q-Line Biotech SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Q-Line Biotech SME IPO?
Q-Line Biotech SME IPO listed on May 29, 2026 at ₹452, against the issue price of ₹343 — a gain of +31.78%.
How did the GMP of Q-Line Biotech SME IPO trend before listing?
The GMP of Q-Line Biotech SME IPO was rising in its final days before listing. The GMP peaked at ₹140 on 21 May 2026. View the day-wise table above for the complete GMP history.
Explore Q-Line Biotech SME IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
